Rituximab–leflunomide combo misses mark in rheumatoid arthritis trial
In a phase III rheumatoid arthritis (RA) trial, the combination of rituximab plus leflunomide has failed to achieve the primary efficacy endpoint of ≥50-percent improvement in American College of Rheumatology criteria (ACR50 response) rates at week 24 compared with leflunomide alone, although the combination confers substantial benefits for secondary endpoints.
